Anti-Müllerian hormone (AMH): Regulator and marker of ovarian function;Hormone anti-müllérienne (AMH): Régulateur et marqueur de la fonction ovarienne

Annales d'Endocrinologie

Volumn 71, Issue 3, 2010, Pages 191-197

  van Houten, E L A F ^a   Themmen, A P N ^a   Visser, J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

AMHRII gene; Anti M llerian hormone (AMH); Polycystic ovary syndrome (PCOS)

Indexed keywords

BIOLOGICAL MARKER; FOLLITROPIN; GROWTH FACTOR; MUELLERIAN INHIBITING FACTOR;

ARTICLE; CORRELATION ANALYSIS; DISEASE MARKER; GENETIC VARIABILITY; HORMONE BLOOD LEVEL; HUMAN; MOUSE; NONHUMAN; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; REGULATORY MECHANISM;

ANIMALS; ANTI-MULLERIAN HORMONE; FEMALE; GENOTYPE; HOMEOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; MULLERIAN DUCTS; OVARIAN FOLLICLE; OVARY; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA;

EID: 77952746161     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2010.02.016     Document Type: Article

References (62)

1. Josso N., Cate R.L., Picard J.Y., Vigier B., di Clemente N., Wilson C., et al. Anti-mullerian hormone: the Jost factor. Recent Prog Horm Res 1993, 48:1-59.
2. Lee M.M., Donahoe P.K. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev 1993, 14:152-164.
3. Durlinger A.L.L., Visser J.A., Themmen A.P.N. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction 2002, 124:601-609.
4. Rajpert-De Meyts E., Jorgensen N., Graem N., Muller J., Cate R.L., Skakkebaek N.E. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 1999, 84:3836-3844.
5. Weenen C., Laven J.S., Von Bergh A.R., Cranfield M., Groome N.P., Visser J.A., et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004, 10:77-83.
6. Massague J., Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. Embo J 2000, 19:1745-1754.
7. Visser J.A. AMH signaling: from receptor to target gene. Mol Cell Endocrinol 2003, 211:65-73.
8. Visser J.A., Olaso R., Verhoef-Post M., Kramer P., Themmen A.P.N., Ingraham H.A. The serine/threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling. Mol Endocrinol 2001, 15:936-945.
9. Jamin S.P., Arango N.A., Mishina Y., Hanks M.C., Behringer R.R. Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nat Genet 2002, 32:408-410.
10. Jamin S.P., Arango N.A., Mishina Y., Hanks M.C., Behringer R.R. Genetic studies of the AMH/MIS signaling pathway for Mullerian duct regression. Mol Cell Endocrinol 2003, 211:15-19.
11. Gouedard L., Chen Y.G., Thevenet L., Racine C., Borie S., Lamarre I., et al. Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. J Biol Chem 2000, 275:27973-27978.
12. Baarends W.M., Uilenbroek J.T., Kramer P., Hoogerbrugge J.W., van Leeuwen E.C., Themmen A.P.N., et al. Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 1995, 136:4951-4962.
13. Erickson G.F., Shimasaki S. The spatiotemporal expression pattern of the bone morphogenetic protein family in rat ovary cell types during the estrous cycle. Reprod Biol Endocrinol 2003, 1:9.
14. Hirshfield A.N. Development of follicles in the mammalian ovary. Int Rev Cytol 1991, 124:43-101.
15. McGee E.A., Hsueh A.J. Initial and cyclic recruitment of ovarian follicles. Endocr Rev 2000, 21:200-214.
16. Durlinger A.L.L., Kramer P., Karels B., de Jong F.H., Uilenbroek J.T., Grootegoed J.A., et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 1999, 140:5789-5796.
17. Durlinger A.L.L., Gruijters M.J., Kramer P., Karels B., Ingraham H.A., Nachtigal M.W., et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002, 143:1076-1084.
18. Gigli I., Cushman R.A., Wahl C.M., Fortune J.E. Evidence for a role for anti-Mullerian hormone in the suppression of follicle activation in mouse ovaries and bovine ovarian cortex grafted beneath the chick chorioallantoic membrane. Mol Reprod Dev 2005, 71:480-488.
19. Carlsson I.B., Scott J.E., Visser J.A., Ritvos O., Themmen A.P.N., Hovatta O. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod 2006, 21:2223-2227.
20. Schmidt K.L., Kryger-Baggesen N., Byskov A.G., Andersen C.Y. Anti-Mullerian hormone initiates growth of human primordial follicles in vitro. Mol Cell Endocrinol 2005, 234:87-93.
21. Visser J.A., Durlinger A.L., Peters I.J., van den Heuvel E.R., Rose U.M., Kramer P., et al. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice. Endocrinology 2007, 148:2301-2308.
22. Durlinger A.L.L., Gruijters M.J., Kramer P., Karels B., Kumar T.R., Matzuk M.M., et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001, 142:4891-4899.
23. di Clemente N., Goxe B., Rémy J.J., Cate R.L., Josso N., Vigier B., et al. Inhibitory effect of AMH upon aromatase activity and LH receptors of granulosa cells of rat and porcine immature ovaries. Endocrine 1994, 2:553-558.
24. Grossman M.P., Nakajima S.T., Fallat M.E., Siow Y. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril 2008, 89:1364-1370.
25. Andersen C.Y., Byskov A.G. Estradiol and regulation of anti-Mullerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles' fluid. J Clin Endocrinol Metab 2006, 91:4064-4069.
26. Kevenaar M.E., Themmen A.P.N., Rivadeneira F., Uitterlinden A.G., Laven J.S., van Schoor N.M., et al. A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum Reprod 2007, 22:2382-2388.
27. Kevenaar M.E., Themmen A.P.N., Laven J.S., Sonntag B., Fong S.L., Uitterlinden A.G., et al. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum Reprod 2007, 22:1547-1554.
28. Franks S. Polycystic ovary syndrome. N Engl J Med 1995, 333:853-861.
29. Kevenaar M.E., Laven J.S., Fong S.L., Uitterlinden A.G., de Jong F.H., Themmen A.P.N., et al. A functional anti-mullerian hormone gene polymorphism is associated with follicle number and androgen levels in polycystic ovary syndrome patients. J Clin Endocrinol Metab 2008, 93:1310-1316.
30. Lee W.S., Otsuka F., Moore R.K., Shimasaki S. Effect of bone morphogenetic protein-7 on folliculogenesis and ovulation in the rat. Biol Reprod 2001, 65:994-999.
31. Kevenaar M.E., Themmen A.P.N., van Kerkwijk A.J., Valkenburg O., Uitterlinden A.G., de Jong F.H., et al. Variants in the ACVR1 gene are associated with AMH levels in women with polycystic ovary syndrome. Hum Reprod 2009, 24:241-249.
32. Pellatt L., Hanna L., Brincat M., Galea R., Brain H., Whitehead S., et al. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007, 92:240-245.
33. te Velde E.R., Pearson P.L. The variability of female reproductive ageing. Hum Reprod Update 2002, 8:141-154.
34. Scheffer G.J., Broekmans F.J., Looman C.W., Blankenstein M., Fauser B.C., teJong F.H., et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod 2003, 18:700-706.
35. Kevenaar M.E., Meerasahib M.F., Kramer P., van de Lang-Born B.M., de Jong F.H., Groome N.P., et al. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006, 147:3228-3234.
36. de Vet A., Laven J.S., de Jong F.H., Themmen A.P.N., Fauser B.C. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002, 77:357-362.
37. van Rooij I.A., Broekmans F.J., Scheffer G.J., Looman C.W., Habbema J.D., de Jong F.H., et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005, 83:979-987.
38. Fanchin R., Taieb J., Lozano D.H., Ducot B., Frydman R., Bouyer J. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 2005, 20:923-927.
39. Hehenkamp W.J., Looman C.W., Themmen A.P.N., de Jong F.H., Te Velde E.R., Broekmans F.J. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006, 91:4057-4063.
40. van Rooij I.A., Tonkelaar I., Broekmans F.J., Looman C.W., Scheffer G.J., de Jong F.H., et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004, 11:601-606.
41. van Disseldorp J., Faddy M.J., Themmen A.P.N., de Jong F.H., Peeters P.H., van der Schouw Y.T., et al. Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008, 93:2129-2134.
42. Wallace W.H., Anderson R.A., Irvine D.S. Fertility preservation for young patients with cancer: who is at risk and what can be offered?. Lancet Oncol 2005, 6:209-218.
43. Bath L.E., Wallace W.H., Shaw M.P., Fitzpatrick C., Anderson R.A. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003, 18:2368-2374.
44. Lie Fong S., Laven J.S., Hakvoort-Cammel F.G., Schipper I., Visser J.A., Themmen A.P.N., et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod 2009, 24:982-990.
45. van Beek R.D., van den Heuvel-Eibrink M.M., Laven J.S., de Jong F.H., Themmen A.P.N., Hakvoort-Cammel F.G., et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007, 92:3869-3874.
46. Seifer D.B., MacLaughlin D.T., Christian B.P., Feng B., Shelden R.M. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002, 77:468-471.
47. van Rooij I.A., Broekmans F.J., te Velde E.R., Fauser B.C., Bancsi L.F., de Jong F.H., et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002, 17:3065-3071.
48. Broer S.L., Mol B.W., Hendriks D., Broekmans F.J. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009, 91:705-714.
49. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19: 41-47.
50. Escobar-Morreale H.F., San Millan J.L. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007, 18:266-272.
51. Norman R.J., Dewailly D., Legro R.S., Hickey T.E. Polycystic ovary syndrome. Lancet 2007, 370:685-697.
52. Franks S., Gilling-Smith C., Watson H., Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999, 28:361-378.
53. Cook C.L., Siow Y., Brenner A.G., Fallat M.E. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002, 77:141-146.
54. Fallat M.E., Siow Y., Marra M., Cook C., Carrillo A. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril 1997, 67:962-965.
55. Laven J.S., Mulders A.G., Visser J.A., Themmen A.P.N., De Jong F.H., Fauser B.C. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004, 89:318-323.
56. Pigny P., Merlen E., Robert Y., Cortet-Rudelli C., Decanter C., Jonard S., et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003, 88:5957-5962.
57. Piouka A., Farmakiotis D., Katsikis I., Macut D., Gerou S., Panidis D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009, 296:E238-243.
58. Eldar-Geva T., Margalioth E.J., Gal M., Ben-Chetrit A., Algur N., Zylber-Haran E., et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005, 20:1814-1819.
59. Fleming R., Deshpande N., Traynor I., Yates R.W. Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. Hum Reprod 2006, 21:1436-1441.
60. La Marca A., Orvieto R., Giulini S., Jasonni V.M., Volpe A., De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004, 82:970-972.
61. Fleming R., Harborne L., MacLaughlin D.T., Ling D., Norman J., Sattar N., et al. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril 2005, 83:130-136.
62. Piltonen T., Morin-Papunen L., Koivunen R., Perheentupa A., Ruokonen A., Tapanainen J.S. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005, 20:1820-1826.